Index of artpub/2014/302327/

Ritchlin, Christopher
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy : 6-month and 1-year results of the phase 3, multicentre, double-blind, placebocontrolled, randomised PSUMMIT 2 trial
2014
https://ddd.uab.cat/record/302327
[ICO]NameLast modifiedSizeDescription
[PARENTDIR]Parent Directory  -  
[ ]1=Ritchlin,_Christopher2025-11-22 15:53 22  
[ ]2=Efficacy_and_safety_of_the_anti-IL-12...2025-11-22 15:53 328  
[ ]3=20142025-11-22 15:53 5  
[ ]4=3023272025-11-22 15:53 34  
[TXT]302327.dirinfo2025-11-23 05:42 318  
[ ]302327.du2025-11-23 05:42 29  
[TXT]302327.dupdirs2025-11-23 05:42 0  
[TXT]302327.dupfiles2025-11-23 05:42 0  
[TXT]302327.errors2025-11-23 05:42 29  
[IMG]302327.gif2025-11-23 05:42 38K 
[IMG]302327.ico2025-11-23 05:42 12K 
[TXT]302327.info2025-11-23 05:42 13K 
[TXT]302327.md52025-11-23 05:42 45  
[ ]302327.pdf2025-11-23 05:42 1.3M 
[TXT]302327.sha12025-11-23 05:42 53  
[TXT]302327.sha2562025-11-23 05:42 77  
[TXT]302327.stats2025-11-23 05:42 319  
[TXT]302327.txt2025-11-23 05:42 0